Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Patent
1998-03-17
2000-12-26
Burke, Julie
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
530350, 514 2, 4242771, C07K 500, A61K 3512, A61K 3800
Patent
active
061661767
ABSTRACT:
A cDNA molecule that encodes a protein designated Labyrinthin (Lab) is isolated and its nucleotide sequence is determined. The protein, or peptides derived from the protein, are markers useful to define novel classes of cancers. Diagnostic assays for these cancers use antibodies to Lab or nucleotide probes that hybridize with the lab gene or a fragment therefrom. Vaccines useful either to prevent recurrence of cancers in subjects who test positive for Lab (or lab), or to prevent initial occurrence of cancer, use proteins or peptides derived from Lab. Expression of Lab via immunogenic assays is used to monitor effects of cancer treatments. Antisense molecules against lab are used in treatments. Sense molecules of lab are used to restore lost lab function in diseased normal cells, for example, gland cells.
REFERENCES:
patent: 4816402 (1989-03-01), Rosen et al.
patent: 5223604 (1993-06-01), Hodges et al.
Banner, BF et al. (1985) "Application of monoclonal antibody 44-3A6 in the cytodiagnosis and classification of pulmonary carcinomas." Diagnostic Cytopathology, vol. 1, No. 4, pp. 300-307.
Bentz, BG et al. (May 1988) "Expression of the adenocarcinoma-related antigen recognized by monoclonal antibody 44-3A6 in salivary gland neoplasias" Head and Neck Surgery, vol. 118, No. 5, pp. 603-609.
Cajulis, RS et al. (1993) "Monoclonal antibody 44-3A6 as an adjunct in cytodiagnosis of adenocarcinomas in body fluids" Diagnostic Cytopathology, vol. 9, No. 2, pp. 179-183.
Combs, SG et al. (1988) "Expression of the Antigenic Determinant Recognized by the Monoclonal Antibody 44-3A6 on Select Human Adenocarcinomas and Normal Human Tissues." Tumor Biology, vol. 9, pp. 116-122.
Combs, SG et al. (1988) "Pleomorphic Carcinoma of the Pancreas with Osteoclast-Like Giant Cells Expressing an Epithelial-Associated Antigen Detected by Monoclonal Antibody 44-3A6." Diagnostic Cytopathology, vol. 4, No. 4, pp. 316-322.
Duda, RB et al. (1991) Monoclonal Antibody 44-3A6 as a Marker For Breast Carcinoma. Tumor Biology, vol. 12, pp. 254-260.
Gronke, RS et al. (1990) "Partial purification and characterization of bovine liver aspartyl .beta.-hydroxylase." J. Biol. Chem., vol. 265, pp. 8558-8565.
Gronke, RS et al. (May 1989) Aspartyl .beta.-hydroxylase: In vitro hydroxylation of a synthetic peptide based on the structure of the first growth factor-like domain of human factor IX. Proc. Natl. Acad. Sci. USA. vol. 86. pp. 3609-3613.
Jia, S et al. (1992) "cDNA cloning and expression of bovine aspartyl (asparaginyl) .beta.-hydroxylase." J. Biol. Chem., vol. 267, No. 20, pp. 14322-14327.
Jia, S et al. (Jul. 1994) "A fully active catalytic domain of bovine aspartyl (asparaginyl) .beta.-hydroxylase expressed in Escherichia coli: Characterization and evidence for the identification of an active-site region in vertebrate .alpha.-ketoglutarate-dependent dixoygenases." Proc. Natl. Acad. Sci. USA, vol. 91, pp. 7227-7231.
Korioth, F et al. (1994) "Cloning and characterization of the human gene encoding aspartyl .beta.-hydroxylase." Gene, vol. 150, pp. 395-399.
Landis, S. (Jan./Feb. 1998) "Cancer Statistics, 1998" Ca. Cancer J. Clin., vol. 48, pp. 6-9.
Lavaissiere, L et al. (Sep. 1996) "Overexpression of human aspartyl (asparaginyl) .beta.-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma." J. Clin. Invest., vol. 98, pp. 1313-1323.
Lee, I et al. (Jun. 1986) "Malignant Mesotheliomas: Improved Differential Diagnosis From Lung Adenocarcinomas Using Monoclonal Antibodies 44-3A6 and 624A12." Amer. J. Path., vol. 123, pp. 497-507.
Lee, I et al. (Nov. 1985) "Immunohistochemical analysis of human pulmonary carcinomas using monoclonal antibody 44-3A6." Cancer Research, vol. 45, pp. 5813-5817.
Piehl MR, et al. (1988) "Immunohistochemical Identification of Exocrine and Neuroendocrine Subsets of Large Cell Lung Carcinomas." Path. Res. Prac. vol. 183, pp. 675-682.
Radosevich JA, et al. (1990) "Immunohistochemical analysis of differentiation markers for nonsmall-cell lung cancer" Lung Cancer Differentiation. Lung Biology in Health and disease, pp. 195-216.
Radosevich JA, et al. (1988) "Monoclonal antibody assays for lung cancer." In vitro diagnosis of human tumors using monoclonal antibodies. pp. 101-121.
Radosevich, JA et al. (1991) "Cell Cycle and Electron Microscopic Evaluation of the Adenocarcinoma Antigen Recognized by the Monoclonal Antibody 44-3A6." Br. J. Cancer, vol. 63, supp. XIV, pp. 86-87.
Radosevich, JA et al. (1991) "Expression of the epitope recognized by the monoclonal antibody 44-3A6 during human fetal development." Tumor Biology, vol. 12, pp. 321-329.
Radosevich, JA et al. (1990) "Immunohistochemical analysis of human adenocarcinomas of the lung using the monoclonal antibody 44-3A6" Tumor Biology, vol. 11, pp. 181-188.
Radosevich, JA et al. (Nov. 1985) "Monoclonal antibody 44-3A6 as a probe for a novel antigen found on human lung carcinomas with glandular differentiation." Cancer Research, vol. 45, pp. 5805-5812.
Siddiqui, FS et al. (1992) "Changes in the expression of the tumor-associated antigen recognized by monoclonal antibody 44-3A6 in A549 cells due to calcium." Tumor Biology, vol. 13, pp. 142-151.
Sinkule, J et al. (1991) "Monoclonal antibody 44-3A6 Douxorubicin Immunoconjugates: Comparative In Vitro Anti-Tumor Efficacy of Different Conjugation Methods." Tumor Biology, vol. 12, pp. 198-206.
Spagnolo, DV et al. (Mar. 1991) "The use of monoclonal antibody 44-3A6 in cell blocks in the diagnosis of lung carcinoma, carcinomas metastatic to lung and pleura, and pleural malignant mesothelioma." Am. J. Clinical Pathology, vol. 95, No. 3, pp. 322-329.
Stahel, RA et al. (1994) "Third International Workshop on Lung Tumor and Differentiation Antigens: Overview of the Results of the Central Data Analysis" Int. J. Cancer, supplement 8, pp. 6-14.
Wang, Q et al. (Jul. 25, 1991) "Bovine liver aspartyl .beta.-hydroxylase." J. Biological Chemistry, vol. 266, No. 21, pp. 14004-14010.
Yew, WW et al. (1991) "Application of monoclonal antibody 44-3A6 in the cytological diagnosis of pleural effusion and histological correlation in lung carcinoma" Lung Cancer, vol. 7, pp. 309-316.
Radosevich et al Clin Research 41(3) 697-A, 1993.
Radosevich et al Tumor Biology vol. 17(1) 14, 1996.
Rodasevich et al Tumor Biol vol. 18(1) 12, 1997.
Jia et al, cDNA Cloning and Expression of Bovine Aspartyl (Asparaginyl) Beta-Hydroxylase, J. Biol. Chem. 267 (20): 14322-14327, Jul. 15, 1992.
Korioth et al, Cloning and characterization of the human gene encoding aspartyl Beta-hydroxylase, Gene 150:395-399, Aug. 1994.
Reeck et al, "Homology" in Proteins and Nucleic Acids: A Terminology Muddle and a Way out of It, Cell 50:667, Aug. 28, 1987.
Roger Lewin, When Does Homology Mean Something Else?, Science 237: 1570, Mar. 1987.
Burke Julie
ImmvaRx, Inc.
Martin Alice O.
LandOfFree
Cancer marker protein and peptides thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer marker protein and peptides thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer marker protein and peptides thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-996089